Literature DB >> 21482449

FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria.

Hongcheng Sun1, Mujian Teng, Jie Liu, Dong Jin, Junyi Wu, Dongwang Yan, Junwei Fan, Xuebin Qin, Huamei Tang, Zhihai Peng.   

Abstract

Molecular biomarker has been proposed to improve patient selection and post-transplant prognostication, but rare achievement has been made. In the present study, Forkhead box M1 (FOXM1) expression and its prognostic role have been investigated in hepatocellular carcinoma (HCC) treated by orthotopic liver transplantation (OLT). We found that the notably higher level of FOXM1 in tumors was associated with malignant pathological features of HCC and unfavorable outcome after OLT. The status of FOXM1 expression combined with the Milan criteria could make the prognostication more accurate and may be of particular interest for expanding the criteria in selecting transplant candidates.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482449     DOI: 10.1016/j.canlet.2011.03.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  29 in total

Review 1.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.

Authors:  Vaibhav Chand; Akshay Pandey; Dragana Kopanja; Grace Guzman; Pradip Raychaudhuri
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

Review 3.  Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology.

Authors:  Jan Hansmann; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

4.  FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.

Authors:  Nuo Xu; Xin Zhang; Xun Wang; Hai-yan Ge; Xiao-ying Wang; David Garfield; Ping Yang; Yuan-lin Song; Chun-xue Bai
Journal:  Acta Pharmacol Sin       Date:  2012-03-26       Impact factor: 6.150

5.  Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.

Authors:  Dragana Kopanja; Akshay Pandey; Megan Kiefer; Zebin Wang; Neha Chandan; Janai R Carr; Roberta Franks; Dae-Yeul Yu; Grace Guzman; Ajay Maker; Pradip Raychaudhuri
Journal:  J Hepatol       Date:  2015-03-28       Impact factor: 25.083

6.  Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.

Authors:  Ji-chao Wei; Fan-di Meng; Kai Qu; Zhi-xin Wang; Qi-fei Wu; Ling-qiang Zhang; Qing Pang; Chang Liu
Journal:  Acta Pharmacol Sin       Date:  2015-01-05       Impact factor: 6.150

Review 7.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

8.  Overexpression of FOXM1 as a target for malignant progression of esophageal squamous cell carcinoma.

Authors:  Liang Song; Xiaohang Wang; Zhen Feng
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

9.  Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6.

Authors:  Hongcheng Sun; Huamei Tang; Dacheng Xie; Zhiliang Jia; Zhenyu Ma; Daoyan Wei; Lopa Mishra; Yong Gao; Shaojiang Zheng; Keping Xie; Zhihai Peng
Journal:  Clin Cancer Res       Date:  2015-09-02       Impact factor: 12.531

10.  Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.

Authors:  Taro Yamashita; Azusa Kitao; Osamu Matsui; Takehiro Hayashi; Kouki Nio; Mitsumasa Kondo; Naoki Ohno; Tosiaki Miyati; Hikari Okada; Tatsuya Yamashita; Eishiro Mizukoshi; Masao Honda; Yasuni Nakanuma; Hiroyuki Takamura; Tetsuo Ohta; Yasunari Nakamoto; Masakazu Yamamoto; Tadatoshi Takayama; Shigeki Arii; XinWei Wang; Shuichi Kaneko
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.